Taysha IPO Presentation Deck

Safety: TSHA-102 did not cause adverse behavioral side effects in WT mice Aggregate score 12 10 8 6 2 8 12 16 20 24 Age (weeks) Mice were dosed P28-35 28 32 12% (3/24) of AAV9/mini-treated WT mice developed lesions and prolapses 0% (0/24) of AAV9/miRARE-treated WT mice developed lesions and prolapses T 00 0 vg, n=20 1x10¹¹ vg AAV9/MECP2(v2), n=12 1x10¹1 vg AAV9/mini, n=12 - 1x10¹¹ vg TSHA-102, n=12 - 1x10¹2 vg AAV9/MECP2(v2), n=10 1x10¹2 vg AAV9/mini, n=12 1x10¹2 vg TSHA-102, n=9 *p<0.05 35

View entire presentation